In HCC cells, tankyrase inhibitors that upregulate members of the angiomotion family as well as aurokinase inhibitors restricted tumor cell growth by modification of YAP activity (Jia et al., 2017; Liu et al., 2017). Here, YAP1 is linked to hepatocellular carcinoma.